Prerequisites for a dry powder inhaler for children with cystic fibrosis-Reference-Cited by-同舟云学术

Prerequisites for a dry powder inhaler for children with cystic fibrosis

Published:2017-08-11 Issue:8 Volume:12 Page:e0183130
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Lexmond Anne J.^ORCID,Hagedoorn Paul,Frijlink Henderik W.,Rottier Bart L.,de Boer Anne H.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference18 articles.

1. The clinical relevance of dry powder inhaler performance for drug delivery;P Demoly;Respir Med,2014

2. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD;F Lavorini;Respir Med,2008

3. Influence of airway calibre on the intrapulmonary dose and distribution of inhaled aerosol in normal and asthmatic subjects;KF Chung;Eur Respir J,1988

4. Comparative measurement of lung deposition of inhaled fine particles in normal subjects and patients with obstructive airway disease;CS Kim;Am J Respir Crit Care Med,1997

5. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older;HA Tiddens;J Aerosol Med,2006

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Climate Policy and Pediatric Asthma: How Transition to Nonhydrofluorocarbon Propellants Will Disproportionately Impact Children;Annals of the American Thoracic Society;2024-09

2. Levofloxacin dry powder inhaler for high dose delivery;Powder Technology;2024-01

3. Characterization of Pediatric Extrathoracic Aerosol Deposition with Air-Jet Dry Powder Inhalers;2024

4. Overcoming barriers in cystic fibrosis therapy through inhalational lipid nanoparticles: Challenges and advances;Journal of Drug Delivery Science and Technology;2023-11

5. Development of an inhalable antiviral powder formulation against respiratory syncytial virus;Journal of Controlled Release;2023-05